Highlights from Lilly’s Alzheimer’s Disease Pipeline at the Alzheimer’s Association International Conference® 2018 (AAIC® 2018)

July 20, 2018

INDIANAPOLIS, July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company’s Alzheimer’s disease pipeline will be presented at the Alzheimer’s Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly’s focus on making a meaningful difference in the lives of people living with Alzheimer’s through clinical development and collaboration.

“Lilly’s commitment to Alzheimer’s research continues,” said Phyllis Ferrell, vice president, Global Alzheimer’s Disease Platform Team. “The research findings we are sharing at this year’s meeting highlight our ongoing efforts to find solutions that may lead to a disease-modifying therapy. The patients and their loved ones we aim to help can’t quit, and neither will we.”

Studies being presented about Lilly molecules include (please note, all times listed below are Central Daylight Time):

**Alzheimer’s Disease Care Environment**

- Patterns of change in dependence levels for community dwelling Alzheimer’s patients: 36-month results from the GERAS observational study
  
  *Poster presentation, Sunday, July 22, 9:30AM-4:15PM*

- Do the minimal clinically important difference estimates for clinical outcome assessments for Alzheimer’s disease differ by disease severity?
  
  *Poster presentation, Monday, July 23, 9:30AM-4:15PM*

- Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European multinational project to develop and test innovative patient engagement strategies
  
  *Poster presentation, Tuesday, July 24, 9:30AM-4:15PM*

- Baseline findings from GERAS-US: a longitudinal cohort study of resource use and costs of mild cognitive impairment and mild dementia due to Alzheimer’s Disease (AD) in the United States
  
  *Oral presentation, Thursday, July 26, 11:45AM-12:00PM*

**N3pG mAb and BACE Inhibitor Combination**

- Trailblazer-ALZ, a Phase 2 Disease-Modification Combination Therapy Trial Targeting Multiple Mechanisms of Action Along the Amyloid Pathway
  
  *Poster presentation, Wednesday, July 25, 9:30AM-4:15PM*

**N3pG mAb**

- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813, a β-amylloid Plaque-specific Antibody, in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease or Mild to Moderate Alzheimer’s Dementia
  
  *Oral presentation, Sunday, July 22, 2:00-2:15PM*

**Lanabecestat**

- Lanabecestat Does Not Affect Pharmacokinetics of the BCRP Substrate Rosuvastatin
  
  *Poster presentation, Sunday, July 22, 9:30AM-4:15PM*

- Lanabecestat: Screening Performance from the AMARANTH Study
  
  *Poster presentation, Wednesday, July 25, 9:30AM-4:15PM*

- Baseline Characteristics of Participants Randomized in the Phase 2/3 AMARANTH Study
  
  *Oral presentation, Wednesday, July 25, 2:45-3:00PM*

**Tau mAb**

- The Use of the Digital Clock Drawing Test (DCTclock™) in the Screening Phase of Clinical Trials for Alzheimer’s...
Solanezumab

- The relationship between Tau PET and other AD biomarkers in autosomal dominant Alzheimer disease
  - Poster presentation, Saturday, July 21, 12:30-1:45PM
  - Oral presentation, Tuesday, July 24, 4:45-5:00PM
- The relationship between Tau PET and age across the lifespan
  - Oral presentation, Saturday, July 21, 8:45-9:00AM
  - Poster presentation, Monday, July 23, 9:30AM-4:15PM
- Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Research: The A4 Experience
  - Oral presentation, Sunday, July 22, 8:00-8:15AM
- The Anti-Amyloid Treatment in Asymptomatic AD (A4) Study - Report of Screening Data Results
  - Oral presentation, Sunday, July 22, 8:15-8:30AM
- DIAN-TU Adaptive Prevention Trial Launch and Baseline Data
  - Oral presentation, Sunday, July 22, 8:30-8:45AM
- Predicting Amyloid Burden in Screening for Preclinical AD Prevention Trials
  - Oral presentation, Sunday, July 22, 9:00-9:15AM
- Tau PET in A4: Preliminary Report
  - Poster presentation, Wednesday, July 25, 9:30AM-4:15PM
- Computerized Cognitive Composite (C3) Performance Differences between Aβ+ and Aβ- normal older adults screened for the A4 (Anti-Amyloid in Asymptomatic AD) Study
  - Poster presentation, Wednesday, July 25, 9:30AM-4:15PM
- Brain Amyloid Burden, Sleep, and circadian Rest/Activity Rhythms: Baseline Findings from A4 and LEARN
  - Poster presentation, Wednesday, July 25, 9:30AM-4:15PM

Selective BACE 1 Inhibitor

- The role of BACE1 Inhibition on Aβ Pathology in Aged PDAPP Mice
  - Poster presentation, Monday, July 23, 9:30AM-4:15PM

Biomarkers in Alzheimer’s Disease

- Standardization, Quality Control & Regulated Issues for Fluid Biomarkers (Topic 5: Workshop – The Basics of Fluid Biomarkers in Alzheimer’s Disease)
  - Workshop presentation, Friday, July 20, 11:30AM-12:15PM
- Comparison between Three Volumetric MRI Z-Score Norming Methods across the Alzheimer Disease Spectrum
  - Poster presentation, Saturday, July 21, 12:30-1:45PM; Sunday, July 22, 9:30AM-4:15PM
- Age-Normed Diffusion Basis Spectrum Imaging (DBSI) Cell Ratios to Assess Neuroinflammation in Alzheimer’s Disease Clinical Trials
  - Poster presentation, Saturday, July 21, 12:30-1:45PM; Tuesday, July 24, 9:30AM-4:15PM
- A Simple Method for Defining Atrophy Subtypes in Individual Subjects across the Alzheimer Disease Spectrum
  - Poster presentation, Saturday, July 21, 12:30-1:45PM; Wednesday, July 25, 9:30AM-4:15PM
- Subtypes of Neurodegeneration in Alzheimer Disease: A Head-to-Head Comparison of Four Brain Atrophy Subtype Algorithms in ADNI
  - Poster presentation, Sunday, July 22, 9:30AM-4:15PM
- Measurement of endogenous mouse tau in cerebrospinal fluid from aged PDAPP mice following treatment with Aβ lowering compounds
  - Poster presentation, Sunday, July 22, 9:30AM-4:15PM
- Mapping Genomic Consequences of Alzheimer’s Disease Pathology in Amyloid and Tau Mouse
  - Poster presentation, Tuesday, July 24, 9:30AM-4:15PM

Flortaucipir PET Tracer

- Lobar classification of tau PET images in the EXPEDITION3 trial
  - Poster presentation, Saturday, July 21, 12:30-1:45PM
  - Oral presentation, Tuesday, July 24, 4:30-4:45PM
- Alzheimer Disease Tau PET Subtypes in the ADNI Sample
  - Poster presentation, Wednesday, July 25, 9:30AM-4:15AM

About Alzheimer’s Disease
Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition.¹ Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.² There are currently an estimated 50 million people living with dementia around the world, with numbers expected to increase to nearly 75 million by 2030 and 132 million by 2050. Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case approximately every 3 seconds. The current total annual societal and economic estimated cost of dementia is $818 billion USD worldwide and this year may rise above a trillion USD.³

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about investigational treatments and diagnostics for Alzheimer's disease and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that these investigational compounds or diagnostics will achieve primary study endpoints or receive regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.


Refer to: Nicole Hebert; nicole_hebert@lilly.com; 317-701-9984 (media)
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (investors)


SOURCE Eli Lilly and Company